A Randomized, Open-label, Single-dose, Parallel-design, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers
Latest Information Update: 02 Feb 2026
At a glance
- Drugs DW 5524 (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors Daewon Pharmaceutical
Most Recent Events
- 02 Feb 2026 New trial record